- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
This Week in Managed Care: July 18, 2015
The top story was Marilyn Tavenner became the nation's top healthcare lobbyist when she was named the new president and CEO of America's Health Insurance Plans, plus the controversial new guidelines that called for more Americans to take statins were validated, according to the results of a new study.
This week the top story was the appointment of Marilyn B. Tavenner, former administrator for CMS, as the new president and chief executive officer of America's Health Insurance Plans (AHIP). Former AHIP President Karen Ignagni left the job in May for a new position with EmblemHealth. The new role will make Ms Tavenner, who was elected unanimously by the board of directors, the nation's top healthcare lobbyist.
Last week, the House voted overwhelmingly to pass the 21st Century Cures Act, which advances Big Data, strengthens the National Institutes of Health and precision medicine, and speeds the FDA approval process. The act promotes research in diseases that range from cancer, to multiple sclerosis, to ALS.
A new study in JAMA has validated the 2013 statin guidelines that caused much controversy when the American Heart Association and the American College of College of Cardiology issued them. The guidelines call for more Americans to take statins and the study found that the new guidelines are efficient and cost-effective.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
